The gastrointestinal tract is the largest immune organ in the body and one of the most active sites of peptide signaling. Endogenous peptides regulate everything from mucosal barrier integrity to inflammatory cascades to epithelial cell turnover.

Three peptides dominate the published gut health literature: BPC-157, KPV, and Glutathione. Each operates through a distinct mechanism, and understanding where they overlap — and where they don’t — matters for designing meaningful research protocols.

BPC-157: The Mucosal Repair Peptide

Body Protection Compound-157 is a 15-amino acid fragment derived from human gastric juice protein BPC. First isolated from gastric mucosal extracts in the early 1990s, the published literature on its GI effects is extensive — over 100 peer-reviewed studies spanning three decades.

The core finding across multiple animal models: BPC-157 accelerates mucosal healing. Published data in Journal of Physiology-Paris and Life Sciences documented enhanced healing across multiple injury types:

• Gastric ulcers
• Intestinal anastomoses
• Inflammatory bowel lesions
• NSAID-induced gastric damage
• Alcohol-induced mucosal injury

The mechanism involves upregulation of growth factor expression — particularly VEGF, EGF, and nitric oxide synthase — at wound sites.

Key limitation: The overwhelming majority of BPC-157 data comes from animal models. The peptide has not completed Phase III human trials for any GI indication.

KPV: The Melanocortin Anti-Inflammatory

KPV is the C-terminal tripeptide fragment of alpha-MSH — just three amino acids (Lys-Pro-Val) that retain the parent hormone’s anti-inflammatory signaling without its melanogenic effects.

Mechanism of Action

The GI research on KPV centers on its interaction with NF-κB signaling — the master inflammatory transcription factor. Published data in Journal of Biological Chemistry demonstrated that KPV:

• Enters colonocytes directly
• Inhibits NF-κB nuclear translocation
• Reduces downstream expression of pro-inflammatory cytokines (IL-8, TNF-α)

Oral Delivery Breakthrough

The oral bioavailability angle is significant — most peptides are degraded in the GI tract, but KPV’s small size (just three residues) and nanoparticle delivery preserved biological activity through the intestinal environment.

Glutathione: The Redox Foundation

Glutathione (GSH) is the body’s most abundant endogenous antioxidant — found in virtually every cell. In the gut specifically, it serves as the primary defense against oxidative damage to the intestinal epithelium.

Published research in Free Radical Biology and Medicine and American Journal of Physiology established a bidirectional relationship:

• Inflammation depletes GSH — removing the oxidative stress buffer
• GSH depletion amplifies inflammation — allowing reactive oxygen species to cascade

Published data in Gut journal demonstrated that restoring mucosal GSH levels reduced markers of oxidative stress and improved barrier function in experimental models.

How These Three Peptides Relate

The reason BPC-157, KPV, and Glutathione appear together in gut research isn’t marketing — it’s mechanistic logic:

Together, they address three distinct phases: protection → inflammation control → repair.

Current Research Gaps

The gut peptide field has several notable gaps in the published literature:

• BPC-157 lacks human clinical trial data despite extensive preclinical work
• KPV’s oral bioavailability without nanoparticle delivery systems remains poorly characterized
• Glutathione’s oral absorption is debated — some researchers argue oral GSH is largely degraded before reaching target tissues, while others have published data showing meaningful increases with specific formulations

These gaps represent genuine research opportunities rather than reasons for skepticism. The mechanistic data is strong; the clinical translation work simply hasn’t caught up yet.

Growth hormone is one of those compounds that exists in the space between genuine biology and gym mythology. GH secretagogues — peptides that trigger the body to release its own growth hormone — are more interesting than direct hormone replacement because they work with the body’s existing signaling. Ipamorelin and CJC-1295 are the most researched duo in this space.

Why Secretagogues Over Exogenous GH

Growth hormone is released by the anterior pituitary in response to two main signals:

• GHRH (growth hormone-releasing hormone) — from the hypothalamus, tells the pituitary “release GH now”
• Somatostatin — from the hypothalamus, tells it “stop releasing GH”

Exogenous GH bypasses this system entirely — flooding the bloodstream, suppressing natural release, and disrupting pulsatile patterns. Secretagogues enhance this system — more GH through your normal pituitary, pulsatile pattern preserved, feedback loops intact.

Ipamorelin: The Selective Ghrelin Mimetic

Ipamorelin is a pentapeptide that binds the ghrelin receptor (GHS-R1a). What distinguishes it from other GHRPs is selectivity:

• GH release — robust stimulation through physiologic ghrelin pathways
• Cortisol — no meaningful alteration (most GHRPs increase cortisol)
• Prolactin — no meaningful alteration
• Aldosterone — no meaningful alteration
• Appetite increase — expected side effect from ghrelin receptor activation (feature or bug depending on goals)

CJC-1295: The Extended GHRH Analog

CJC-1295 is a synthetic GHRH analog — mimics the hypothalamic signal that tells the pituitary to release GH, but with extended duration:

The Stack: Why They’re Used Together

Ipamorelin and CJC-1295 work on different parts of the same system:

Research Applications

Body Composition

• Increased lean mass — GH drives protein synthesis rates
• Decreased fat mass — enhanced lipolysis (fat breakdown)
• Improved metabolic markers — glucose metabolism and substrate utilization

Recovery and Performance

• Tissue repair — GH supports protein synthesis and structural recovery
• Glycogen repletion — faster energy store restoration post-training
• Muscle preservation — reduced breakdown during caloric deficit or stress

Metabolic and Anti-Aging

• Blood sugar regulation — GH affects insulin sensitivity and glucose handling
• Age-related GH decline — secretagogues address somatopause through physiologic mechanism
• Bone density support — GH’s role in bone mineral maintenance

Safety Profile

The appeal of secretagogues is partly safety — by working with the body’s signaling rather than replacing hormones:

• Cleaner than exogenous GH — joint pain, carpal tunnel, insulin resistance risks substantially reduced
• Ipamorelin side effects — increased appetite (ghrelin activation), mild and expected
• CJC-1295 side effects — occasional flushing, transient
• Long-term data limited — most studies are short-term; inherent uncertainty about extended use

NAD+ isn’t a peptide. It’s a coenzyme — a small molecule that helps enzymes do their job. So why do we carry it? Because NAD+ research intersects with everything happening in the longevity and regenerative space. Understanding NAD+ helps you understand why combining it with peptide stacks creates more comprehensive anti-aging protocols.

What Is NAD+ and Why Cells Need It

Nicotinamide adenine dinucleotide is found in every cell in the body. It participates in hundreds of metabolic reactions:

• Energy production (ATP synthesis) — foundational to cellular function
• DNA repair — PARP enzymes consume NAD+ to fix DNA breaks
• Cell signaling — sirtuin activation and metabolic regulation
• Mitochondrial function — electron carrier in energy extraction pathways

NAD+ and Mitochondrial Energy

NAD+ is essential for glycolysis and the citric acid cycle — the pathways where cells extract energy from food. Without adequate NAD+, mitochondria can’t operate efficiently:

• Mitochondrial dysfunction — a hallmark of aging; less efficient ATP production, more free radical byproducts
• NAD+ restoration — gives mitochondria the cofactors they need to function
• Published data — cell cultures from aged animals show improved ATP production when NAD+ is restored to youthful levels

NAD+ and DNA Repair

PARP enzymes are DNA repair systems that use NAD+ as fuel. The aging problem is twofold:

Research shows improved DNA repair in aged cells when NAD+ levels are restored — significant for cancer prevention, chromosomal stability, and preventing age-driving mutations.

NAD+ and Sirtuins: The Longevity Enzymes

Sirtuins are enzymes that require NAD+ as a cofactor and regulate longevity-related processes:

• DNA repair coordination — sirtuin-mediated repair pathways
• Metabolic health regulation — glucose and lipid handling
• Stress resistance — cellular defense against oxidative and metabolic stress
• Senescence prevention — may help regulate and clear senescent cells

NMN vs. NR: Choosing a Precursor

NAD+ is too large to cross cell membranes directly, so researchers use precursors the body converts to NAD+:

Both raise NAD+ levels. Both appear safe. Effects seem comparable in many contexts.

The Honest Assessment

• Does it work? — yes, NMN and NR raise NAD+ levels in cells and tissues in preclinical models and short-term human studies
• Animal data — improvements in mitochondrial function, metabolic health, and aging markers
• Human data — some clinical trials showing improved muscle strength, metabolic markers, and blood sugar in older adults
• Long-term lifespan data — not yet available in humans; would take decades to establish

Why We Carry NAD+ Alongside Peptides

GHK-Cu and BPC-157 work in the context of mitochondrial function, energy production, and cellular repair capacity. NAD+ is foundational to all of that:

• Better cellular energy — peptides need energized cells to exert their effects
• Better DNA repair — supports the genomic integrity that peptide signaling depends on
• Better sirtuin activation — enhances the longevity context in which regenerative peptides operate

GLP-1 receptor agonists have dominated metabolic research since 2023. With three major compounds now widely available, understanding their differences is essential for designing effective protocols.

Understanding the GLP-1 Receptor System

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by intestinal L-cells in response to food intake. It plays a central role in glucose homeostasis through several interconnected mechanisms:

• Insulin secretion — stimulates glucose-dependent insulin release from pancreatic beta cells
• Glucagon suppression — reduces glucagon release, lowering hepatic glucose output
• Gastric emptying — slows transit, extending nutrient absorption time
• Appetite signaling — modulates hypothalamic pathways to reduce food intake

Semaglutide: The GLP-1 Selective Agonist

Semaglutide is a modified GLP-1 analog with a C-18 fatty acid chain that enables albumin binding, dramatically extending its half-life. This was the compound that catalyzed the current wave of metabolic research interest and remains the most extensively studied GLP-1 agonist.

Research Applications

• Obesity models — appetite suppression via hypothalamic signaling and delayed gastric emptying
• Type 2 diabetes — improved insulin sensitivity with high GLP-1R selectivity
• Cardiovascular risk — established data from large-scale clinical trials
• NASH/MAFLD — moderate impact on hepatic fat accumulation

View Semaglutide — $75 →

Tirzepatide: The Dual GLP-1/GIP Agonist

Tirzepatide represents a paradigm shift in incretin research by engaging both GLP-1 and GIP receptors simultaneously. The GIP component adds metabolic effects that GLP-1 alone cannot achieve, particularly in fat tissue metabolism and insulin sensitivity.

Research Applications

• Advanced obesity models — dual mechanism produces effects neither receptor achieves independently
• Lipid metabolism — GIP receptor activation enhances fat oxidation
• Tolerability studies — GIP engagement appears to reduce nausea vs pure GLP-1 agonists
• Comparative protocols — head-to-head studies against semaglutide

View Tirzepatide — $65 →

Retatrutide: The Triple Agonist

Retatrutide adds a third receptor — the glucagon receptor — creating the first triple incretin agonist available for research. The glucagon component introduces direct effects on energy expenditure and hepatic lipid metabolism that dual agonists lack.

Research Applications

• NASH/MAFLD liver research — glucagon receptor activation specifically targets hepatic fat reduction
• Energy expenditure — glucagon component increases basal metabolic rate
• Advanced obesity models — highest efficacy of any incretin compound studied to date
• Multi-receptor pharmacology — broadest receptor engagement for mechanistic studies

View Retatrutide — $135 →

Head-to-Head Comparison

Which Compound Is Right for Your Research?

All three compounds are available from Blank Peptides with full third-party COA documentation and research-grade purity verification.

Your digestive system does more than break down food — it’s a signaling system that talks directly to your brain and pancreas. GLP-1 (glucagon-like peptide-1) is a key player: a gut hormone that triggers insulin release, signals satiety, and slows stomach emptying. The innovation behind GLP-1 receptor agonists was straightforward — if natural signaling is broken, boost it artificially with synthetic peptides that activate the same pathways.

The Incretin Effect: How Your Gut Talks to Your Brain

GLP-1 travels through your bloodstream and docks onto receptors in the pancreas, brain appetite centers, heart, and blood vessels. It performs several critical functions:

• Insulin release — triggers glucose-dependent insulin secretion from pancreatic beta cells
• Satiety signaling — communicates fullness to hypothalamic appetite centers
• Gastric slowing — delays stomach emptying to extend nutrient absorption
• Glucagon suppression — reduces hepatic glucose output

Semaglutide: The One That Started the Revolution

The mechanism isn’t about speeding up metabolism — it’s about reducing appetite through genuine physiological satiety signaling. A more sophisticated approach than traditional appetite suppressants.

Tirzepatide: Two Receptors Are Better Than One

Tirzepatide demonstrates that receptor selectivity matters. Two molecular targets instead of one produces measurably different outcomes. This finding has influenced how researchers think about peptide design — instead of maximizing single-pathway activation, what if you carefully balance activation across multiple related pathways?

Retatrutide: The Triple Agonist Nobody Expected

Retatrutide represents the cutting edge of rational peptide design. Researchers identified multiple pathways involved in appetite regulation and metabolic control, then engineered a single molecule to modulate all three. This approach — building one molecule to hit multiple targets — is increasingly common in modern drug development.

What Researchers Are Still Trying to Figure Out

• Long-term sustainability — most trials last 1–2 years; effects at 10 or 20 years remain unknown, and tolerance development is a concern
• Off-target effects — GLP-1 receptors exist throughout the body, meaning systemic effects need thorough investigation
• Rebound effect — appetite returns rapidly after cessation, suggesting the system doesn’t recalibrate
• Individual variation — some people respond dramatically, others minimally; predictive biomarkers are being developed
• Full mechanism mapping — understanding every downstream effect would help design better molecules and predict individual outcomes

We carry all three GLP-1 receptor agonists at Blank Peptides, each verified to >99% purity with independent HPLC analysis. Our commitment to transparent, research-grade quality means your metabolic studies start with materials you can trust.

GLP-1 receptor agonists dominate the peptide research landscape right now. Semaglutide, tirzepatide, and retatrutide have each generated landmark clinical data on body weight reduction — and the published results keep getting more dramatic with each generation of compound. This article breaks down what the peer-reviewed literature actually says, how the three compounds differ mechanistically, and where the research is headed.

The GLP-1 Mechanism: Why These Peptides Reduce Body Weight

Glucagon-like peptide-1 is a naturally occurring incretin hormone. GLP-1 receptor agonists mimic this hormone, binding to receptors in the hypothalamus that regulate appetite signaling. Published research identifies three primary downstream effects:

• Reduced appetite signaling — hypothalamic GLP-1R activation suppresses hunger drive at the neurological level
• Delayed gastric emptying — extends post-meal satiety by slowing digestive transit
• Improved insulin sensitivity — pancreatic beta-cell modulation enhances glucose homeostasis

These mechanisms have been established through decades of incretin biology research, beginning with the discovery of GLP-1’s role in glucose homeostasis in the 1980s and culminating in the large-scale clinical trials of the 2020s.

Semaglutide — The Clinical Benchmark

Semaglutide is a GLP-1 receptor agonist with a ~7-day half-life, enabling once-weekly administration in clinical study designs.

Semaglutide’s long duration of action and extensive published safety dataset make it the reference compound against which newer GLP-1 agonists are benchmarked.

Tirzepatide — Dual Agonism, Larger Effect Size

Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — the first dual incretin agonist with large-scale published data.

Retatrutide — Triple Agonism and Phase 3 Data

Retatrutide adds glucagon receptor agonism to the GLP-1/GIP dual mechanism — the first triple incretin agonist in advanced clinical development.

The glucagon receptor component is notable because glucagon stimulates hepatic energy expenditure and fatty acid oxidation — addressing the energy output side of the equation rather than just appetite suppression. Early published data suggests particularly strong effects on hepatic fat reduction, with implications for NAFLD/NASH research.

Head-to-Head: What the Literature Shows

Each successive generation has produced incrementally larger effect sizes in published trials:

However, direct head-to-head comparison data remains limited, and individual response variability is substantial across all three compounds. Side effect profiles — predominantly GI-related (nausea, diarrhea, constipation) during dose titration — are broadly similar across the class.

Other Peptides in Body Composition Research

Beyond GLP-1 agonists, published research has examined several other peptides in the context of body composition:

• MOTS-c — mitochondrial-derived peptide studied for AMPK-mediated metabolic effects and exercise-mimetic properties
• GH secretagogues (CJC-1295, Ipamorelin) — studied for effects on lean mass preservation during weight loss
• Tesamorelin — GHRH analog with published data specifically on selective visceral adipose tissue reduction